Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome

Validation of a Standard Protocol

Ty B. Carroll; William J. Peppard; David J. Herrmann; Bradley R. Javorsky; Tracy S. Wang; Hina Patel; Katarzyna Zarnecki; James W. Findling

Disclosures

J Endo Soc. 2019;3(1):1-12. 

In This Article

Conclusion

In conclusion, our protocol-driven continuous etomidate infusion demonstrated rapid control of severe hypercortisolism secondary to neoplastic Cushing syndrome without any observed adverse side effects. This protocol should help guide clinical endocrinologists and pharmacists in the management of seriously ill patients with severe hypercortisolism as a bridge to long-term medical therapy or definitive surgical intervention.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....